Abstract: A semiconductor device has a first interconnect structure. A first bridge die is disposed over the first interconnect structure. An encapsulant is deposited over the first bridge die. A second interconnect structure is formed over the first bridge die and encapsulant. A second bridge die is disposed over the second interconnect structure.

Abstract: Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

Abstract: A semiconductor device has a pre-molded discrete electrical component and a first encapsulant deposited over the pre-molded discrete electrical component. A first conductive layer is formed over the first encapsulant and pre-molded discrete electrical component. An electrical component is disposed over the first conductive layer. A second encapsulant is deposited over the electrical component and first conductive layer. A second conductive layer is formed over the second encapsulant. A conductive pillar is formed between the first conductive layer and second conductive layer through the second encapsulant. The pre-molded discrete electrical component has a discrete component and a third encapsulant deposited around the discrete component. The discrete component has an electrical terminal, a finish formed over the electrical terminal, and a third conductive layer formed over the finish.

Abstract: Dome switches can provide inconsistent positive tactile feedback, particularly when depressed around the edges of a corresponding push button as compared to depression at the middle of the push button. Various arrangements intended to render push buttons that incorporate one or more dome switches more consistent in providing positive tactile feedback, while maintaining a reasonable ease and cost of manufacturing, are discussed herein. A push button with consistent edge performance using a single dome switch incorporates a hinge arm that spans button posts. This reduces or eliminates rotation deflection of a button cap caused by the torsional forces on the push button created by depression forces applied by the user at an edge of the push button. As a result, the dome switch provides a predictable and consistent positive tactile feedback to the user similar to that achieved by a centrally applied depression force.

Abstract: A semiconductor device has a plurality of electrical components and an encapsulant deposited over the electrical components. A first saw street of the encapsulant separates a first electrical component from a second electrical component. A first channel is formed in a first surface of the encapsulant within the first saw street to reduce stress. A second channel is formed in a second surface of the encapsulant opposite the first surface and within the first saw street. A third channel is formed in the first surface of the encapsulant and within a second saw street of the encapsulant normal to the first saw street. An RDL is formed over the electrical components. The RDL has an insulating layer formed over the electrical component, and a conductive layer formed over the insulating layer. The insulating layer terminates prior to the first saw street.

Abstract: The present invention relates to therapeutic uses of active agents such as for treating, inhibiting, and/or preventing damage associated with aminoglycoside toxicity. The data establishes that piperlongumine can protect hair cells from aminoglycoside damage within a wide range of concentrations. The range is 0.1 pM to 25 uM. Furthermore, piperlongumine protects renal function, it has a good therapeutic index (TI>200,000), no interference with AG's anti-bacterial activity, and no drug-drug interaction. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed is a PD-L1 inhibitor, and specifically disclosed is a compound of formula (I) as a PD-L1 immunomodulator, a pharmaceutically acceptable salt or an isomer thereof.

Abstract: The present invention provides a fan-out package structure and a method for manufacturing the same. The fan-out package structure includes at least one chip and at least one redistribution layer on a functional surface side of the chip, and the redistribution layer includes a dielectric layer and a metal wiring layer distributed within the dielectric layer. The fan-out package structure further includes at least one dummy wafer on the redistribution layer, and the dummy wafer is insulated from the chip and in contact with the metal wiring layer. By providing the dummy wafer on the redistribution layer and configuring the dummy wafer to connect to the metal wiring layer, the dummy wafer can not only function to support the structure and suppress the warpage, but also form a continuous heat dissipation channel, thereby improving thermal management capability of the fan-out package structure.

Abstract: In one aspect, use of Afatinib as an active agent to treat a hearing loss and to prevent a hearing loss, and methods of treating and/or preventing hearing loss or disorders using the compositions are disclosed. In particular, a method for treating sensorineural hearing loss, including the steps of delivering to a patient in need thereof a composition comprising a therapeutically effective amount of Afatinib. or pharmaceutically acceptable salt thereof is provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A semiconductor device has a semiconductor die. A first contact pad, second contact pad, and third contact pad are formed over the semiconductor die. An under-bump metallization layer (UBM) is formed over the first contact pad, second contact pad, and third contact pad. The UBM electrically connects the first contact pad to the second contact pad. The third contact pad is electrically isolated from the UBM. Conductive traces can be formed extending between the first contact pad and second contact pad under the UBM. A fourth contact pad can be formed over the first contact pad and a fifth contact pad can be formed over the second contact pad. The UBM is then formed over the fourth and fifth contact pads.

Abstract: This disclosure provides for methods, kits and pharmaceutical compositions comprising an inhibitor of EGFR signaling for the treatment of hearing loss. In particular, one such EGFR inhibitor, Dabrafenib, is a therapeutic candidate for treating cisplatin-induced and/or noise-induced hearing loss.

Abstract: In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice. In one aspect, (E)-1-(3-(3,4,5-trimethoxy phenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.

Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Abstract: A semiconductor device has an RDL substrate and hybrid substrate with a plurality of bumps. The hybrid substrate is bonded to the RDL substrate. An encapsulant is deposited around the hybrid substrate and RDL substrate with the bumps embedded within the encapsulant. The hybrid substrate has a core substrate, first RDL formed over a first surface of the core substrate, conductive pillars formed over the first RDL, and second RDL over a second surface of the core substrate. A portion of the encapsulant is removed to expose the conductive pillars. The RDL substrate has a carrier and RDL formed over a surface of the carrier. The carrier is removed after bonding the hybrid substrate to the RDL substrate. Alternatively, the RDL substrate has a core substrate, first RDL formed over a first surface of the core substrate, and second RDL formed over a second surface of the core substrate.

Abstract: A semiconductor device has a first hybrid substrate with a first thickness, and a second hybrid substrate with a second thickness different from the first thickness of the first hybrid substrate. An encapsulant is deposited around the first hybrid substrate and second hybrid substrate. A portion of the first hybrid substrate and a portion of the second hybrid substrate and a portion of the encapsulant can be removed after encapsulation to achieve uniform thickness for the first hybrid substate and second hybrid substrate. The first hybrid substrate has an embedded substrate, a first interconnect structure formed over a first surface of the embedded substrate, and a second interconnect structure formed over a second surface of the embedded substrate opposite the first surface of the embedded substrate. A plurality of conductive pillars is formed over the first interconnect structure. A plurality of conductive vias is formed through the embedded substrate.

Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Abstract: Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of cisplatin- or noise-induced hearing loss. In one aspect, use of compounds as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice. In one aspect, (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-S,6-dihydropyridin-2(1H)-one and derivatives can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. Momelotinib and Fedratinib exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice when administered prophylactically. In one aspect, Momelotinib or Fedratinib can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.